Speak with me

Recent changes.

Catalyst dates move. This page lists every date on the biotech catalyst calendar that has changed in the last 30 days, and every row withdrawn in that period, with the date it moved from. A row that moves keeps its identity, so a calendar subscription updates the event in place rather than adding a second one. Nothing is ever deleted quietly.

Last compiled .

WasNowLaneCompanyEventSource
8 Jan 2027ClinicalSanofiAs of 26 October 2026, Sanofi estimated primary completion of a Phase 2 trial in Plasma Cell Myeloma Refractory, on 1 April 2027.NCT06356571
31 Oct 2026ClinicalUCB Biopharma SRLAs of 26 October 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Stereotypical Prolonged Seizures, on 29 March 2027.NCT05077904
30 Nov 2026ClinicalTolmar Inc.As of 23 October 2026, Tolmar estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 January 2027.NCT04906395
31 Dec 2026ClinicalAlbireo, an Ipsen CompanyAs of 23 October 2026, Albireo, an Ipsen estimated primary completion of a Phase 3 trial in Alagille Syndrome, on 15 February 2027.NCT05035030
19 Oct 2026ClinicalPfizerAs of 23 October 2026, Pfizer estimated primary completion of a Phase 2 trial in Atopic Dermatitis, on 12 November 2026.NCT05995964
1 Dec 2026ClinicalSichuan Baili Pharmaceutical Co., Ltd.As of 23 October 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gynecological Malignancies, in January 2027.NCT06131450
1 Sept 2026ClinicalLubris Bio Pty LtdAs of 26 October 2026, Lubris Bio Pty estimated primary completion of a Phase 2 trial in Ocular Graft Versus Host Disease, in March 2027.NCT07118254
24 Jan 2027ClinicalDompé Farmaceutici S.p.AAs of 22 October 2026, Dompé Farmaceutici S.p.A estimated primary completion of a Phase 2 trial in Dry Eye Disease (DED), on 27 December 2026.NCT07503886
4 Sept 2026ClinicalClear Scientific, Inc.As of 21 October 2026, Clear Scientific estimated primary completion of a Phase 2 trial in Methamphetamine Intoxication, on 29 October 2026.NCT06721494
23 Dec 2026ClinicalCorxel PharmaceuticalsAs of 15 September 2026, Corxel Pharmaceuticals estimated primary completion of a Phase 2 trial in Type II Diabetes Mellitus, on 16 April 2027.NCT07340320
1 Feb 2027ClinicalargenxAs of 16 October 2026, argenx estimated primary completion of a Phase 2 trial in Systemic Sclerosis (SSc), in March 2027.NCT06655155
5 Sept 2026ClinicalH. Lundbeck A/SAs of 16 October 2026, H. Lundbeck estimated primary completion of a Phase 3 trial in Chronic Migraine in Children, on 26 March 2027.NCT04965675
30 Sept 2026ClinicalAstraZenecaAs of 15 October 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Metastatic Non-small Cell Lung Cancer, on 11 January 2027.NCT06417814
15 Oct 2026ClinicalSolid Biosciences Inc.As of 15 October 2026, Solid Biosciences estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 30 November 2026.NCT03368742
31 Aug 2026ClinicalAstellas Pharma Global Development, Inc.As of 14 October 2026, Astellas Pharma Global Development estimated primary completion of a Phase 2 trial in Pancreatic Cancer, on 31 October 2026.NCT03816163
31 Aug 2026ClinicalKyowa Kirin Co., Ltd.As of 14 October 2026, Kyowa Kirin Co. estimated primary completion of a Phase 2 trial in Diabetic Macular Edema (DME), on 31 October 2026.NCT06116916
31 Aug 2026ClinicalMediLink Therapeutics (Suzhou) Co., Ltd.As of 14 October 2026, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Non Small Cell Lung Cancer, on 31 January 2027.NCT07202364
1 Jan 2027ClinicalCoya TherapeuticsAs of 13 October 2026, Coya Therapeutics estimated primary completion of a Phase 3 trial in Amyotrophic Lateral Sclerosis (ALS), in April 2027.NCT07161999
15 Jan 2027ClinicalMoonLake Immunotherapeutics AGAs of 9 October 2026, MoonLake Immunotherapeutics estimated primary completion of a Phase 3 trial in Arthritis, Psoriatic, on 4 January 2027.NCT06641089
18 Nov 2026ClinicalCSL BehringAs of 15 October 2026, CSL Behring estimated primary completion of a Phase 3 trial in Complex Cardiovascular Surgery With Cardiopulmonary Bypass, on 6 April 2027.NCT07094087
18 Sept 2026ClinicalHan Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairAs of 8 October 2026, Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair estimated primary completion of a Phase 3 trial in sCLC, on 18 December 2026.NCT07145333
31 Dec 2026ClinicalHoffmann-La RocheAs of 8 October 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in cancer, on 30 November 2026.NCT03148418
1 Oct 2026ClinicalIngenia Therapeutics INCAs of 7 October 2026, Ingenia Therapeutics estimated primary completion of a Phase 2 trial in Healthy Volunteers, in December 2026.NCT07231679
19 Sept 2026ClinicalTeva Branded Pharmaceutical Products R&D LLCAs of 6 October 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 2 November 2026.NCT06664619
1 Dec 2026ClinicalTBF Genie TissulaireAs of 6 October 2026, TBF Genie Tissulaire estimated primary completion of a Phase 2 trial in Osteoarthritis Hand, in November 2026.NCT06038331
2 Apr 2027ClinicalAstraZenecaAs of 6 October 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Staphylococcus Aureus, on 8 March 2027.NCT06749457
1 Dec 2026ClinicalVantive Health LLCAs of 5 October 2026, Vantive Health estimated primary completion of a Phase 3 trial in Regional Citrate Anticoagulation (RCA), in January 2027.NCT05399537
1 Nov 2026ClinicalBeOne MedicinesAs of 5 October 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in B-cell Malignancy, in March 2027.NCT05006716
30 Jan 2027ClinicalHoffmann-La RocheAs of 2 October 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Moderately to Severely Active Ulcerative Colitis, on 29 October 2026.NCT06588855
1 Feb 2027ClinicalIonis Pharmaceuticals, Inc.As of 18 September 2026, Ionis Pharmaceuticals estimated primary completion of a Phase 2 trial in Prion Disease, in April 2027.NCT06153966
6 Nov 2026ClinicalMerck Sharp & Dohme LLCAs of 2 October 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hodgkin Lymphoma, on 12 February 2027.NCT03407144
16 Dec 2026ClinicalMerck Sharp & Dohme LLCAs of 12 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Invasive Fungal Infection, on 31 March 2027.NCT04665037
31 Dec 2026ClinicalNewron Pharmaceuticals SPAAs of 10 September 2026, Newron Pharmaceuticals SPA estimated primary completion of a Phase 3 trial in Treatment-resistant Schizophrenia, on 31 March 2027.NCT07184619
31 Dec 2026ClinicalRemedyAs of 19 August 2026, Remedy estimated primary completion of a Phase 2 trial in Post Traumatic Stress Disorder, on 31 March 2027.NCT06044675
31 Oct 2026ClinicalViatris Innovation GmbHAs of 15 September 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 March 2027.NCT05648500
1 Dec 2026ClinicalVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAAs of 30 September 2026, Verona Pharma estimated primary completion of a Phase 2 trial in cOPD, on 1 March 2027.NCT05270525
25 Aug 2026ClinicalSanofiAs of 1 October 2026, Sanofi estimated primary completion of a Phase 2 trial in Graves' Disease, on 11 February 2027.NCT06984627
25 Dec 2026ClinicalBoehringer IngelheimAs of 30 September 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Geographic Atrophy, on 22 December 2026.NCT06769048